Kura Oncology Inc (KURA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.73 (+0.09%), Market cap $0.78B, 52-week low–high $5.54 ~ $12.14.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Financial statements, price targets, institutional (13F) holdings and related news for Kura Oncology Inc are updated in real time on BlackAll Trade.
Kura Oncology Inc trades at $11.73 (+0.09%). Real-time quotes and charts are available on BlackAll Trade.
Kura Oncology Inc has a market cap of about $0.78B.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, rev